Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 19/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159970 | 0.99 | P2RY1 (0.69) | P2RY1P2RY14P2RY2KCNH2KDM4E | |
| SCHEMBL3151066 | 0.91 | P2RY1 (0.66) | P2RY1P2RY14P2RY2KCNH2GAA | |
| SCHEMBL24653694 | 0.90 | P2RY1 (0.69) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3158476 | 0.88 | P2RY1 (0.75) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3150582 | 0.85 | P2RY1 (0.81) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3158047 | 0.82 | P2RY1 (0.77) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3159977 | 0.82 | P2RY1 (0.87) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3157933 | 0.82 | P2RY1 (0.77) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL24654132 | 0.82 | P2RY1 (0.67) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL3259745 | 0.81 | P2RY1 (0.75) | P2RY1P2RY14P2RY2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | claimed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | claimed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| EP-4094762-A1 | TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885P2RY14 14/4885P2RY2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.